Ocugen Inc (OCGN) |
|
0.3234 0.003 (1.06%)
|
10-23 23:49 |
|
Open: |
0.3166 |
Pre. Close: |
0.32 |
|
High:
|
0.3239 |
Low:
|
0.3116 |
|
Volume:
|
2,982,998 |
Market Cap:
|
52M |
|
|
|
|
Ocugen, Inc. engages in the development and commercialization of therapies for eye diseases. The company is headquartered in Malvern, Pennsylvania and currently employs 49 full-time employees. The firm offers a diversified ophthalmology portfolio that includes gene therapies, biologics, and small molecules and targets a range of retinal and ocular surface diseases. The firm is leveraging its modifier gene therapy platform to address genetically diverse inherited retinal disorders and dry age-related macular degeneration (AMD), based on nuclear hormone receptor genes NR2E3 (OCU400) and RORA (OCU410), respectively. The firm is also developing biologic therapies for wet-AMD, diabetic macular edema (DME) and diabetic retinopathy (OCU200), as well as for retinitis pigmentosa (OCU100). |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
0.32 - 0.322 |
0.322 - 0.323 |
|
Low:
|
0.307 - 0.308 |
0.308 - 0.31 |
|
Close:
|
0.318 - 0.32 |
0.32 - 0.322 |
|
Technical analysis |
as of: 2020-10-23 4:47:26 PM |
|
Overall:
|
  |
| Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected. |
| Target: |
Six months: 0.40 One year: 0.45 |
| Support: |
Support1: 0.28 Support2: 0.23 |
| Resistance: |
Resistance1: 0.34 Resistance2: 0.38 |
| Pivot: |
0.33 |
| Moving Average: |
MA(5): 0.32 MA(20): 0.32
MA(100): 0.35 MA(250): 0.43  |
| MACD: |
MACD(12,26): -0.01 Signal(9): -0.01 |
| Stochastic oscillator: |
%K(14,3): 25.58 %D(3): 25.64 |
| RSI: |
RSI(14): 46.99 |
| 52-week: |
High: 1.77 Low: 0.17 Change(%): -80.6 |
| Average Vol(K): |
3-Month: 1277038 10-Days: 403537 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and BEARISH in mid-long term.OCGN has closed above bottom band by 38.2%. Bollinger Bands are 77.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to OCGN's normal range. The bands have been in this narrow range for 26 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Headline News |
Fri, 23 Oct 2020
A Look At The Behavior Of Ocugen, Inc. (OCGN) Stock - Stocks Register
Thu, 22 Oct 2020
Ocugen Inc. [OCGN] Is Currently -2.33 below its 200 Period Moving Avg: What Dose This Mean? - The DBT News
Thu, 22 Oct 2020
Riding the Trend or Protecting Profits | Ocugen Inc. (OCGN) - The News Heater
Tue, 20 Oct 2020
Ocugen Inc. (OCGN) volume hits 4.08 million: A New Opening for Investors - News Daemon
Thu, 15 Oct 2020
Ocugen Inc. (OCGN) distance from 20-day Simple moving Average is 2.71%: What to Expect? - The InvestChronicle
Mon, 12 Oct 2020
Hot Stock on Spotlight: Ocugen, Inc. (OCGN) | Armenian American Reporter - Armenian Reporter
|
Financial Analysis |
| Growth |
 |
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
 |
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
|
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
n/a |
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Price to Book Value: |
Outperform |
Discounted cash flow: |
Outperform |
| Return on Assets: |
Underperform |
Price to Earnings: |
Underperform |
| Return on Equity: |
Underperform |
Debt to Equity: |
Outperform |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. (M) |
135 |
| Shares Float (M) |
121 |
|
% Held by Insiders
|
8.15 |
|
% Held by Institutions
|
11.98 |
|
Shares Short (K)
|
4,500 |
|
Shares Short P. Month (K)
|
6,050 |
Stock Financials |
|
EPS
|
|
|
EPS Est This Year
|
|
|
EPS Est Next Year
|
|
|
Book Value (p.s.)
|
|
|
Profit Margin
|
|
|
Operating Margin
|
-31882.73 |
|
Return on Assets (ttm)
|
-60.9 |
|
Return on Equity (ttm)
|
-421.5 |
|
Qtrly Rev. Growth
|
|
|
Gross Profit (p.s.)
|
|
|
Sales Per Share
|
|
|
EBITDA (p.s.)
|
-0.100 |
|
Qtrly Earnings Growth
|
|
|
Operating Cash Flow (M)
|
-19 |
|
Levered Free Cash Flow (M)
|
-18 |
Stock Valuations |
|
PE Ratio
|
|
|
PEG Ratio
|
|
|
Price to Book value
|
|
|
Price to Sales
|
1024.45 |
|
Price to Cash Flow
|
-2.34 |
Stock Dividends |
|
Dividend
|
|
|
Forward Dividend
|
|
|
Dividend Yield
|
|
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
